Compass Therapeutics Statistics Share Statistics Compass Therapeutics has 138.29M
shares outstanding. The number of shares has increased by 0.5%
in one year.
Shares Outstanding 138.29M Shares Change (YoY) 0.5% Shares Change (QoQ) 0% Owned by Institutions (%) 78.82% Shares Floating 100.8M Failed to Deliver (FTD) Shares 556 FTD / Avg. Volume 0.06%
Short Selling Information The latest short interest is 9.53M, so 6.92% of the outstanding
shares have been sold short.
Short Interest 9.53M Short % of Shares Out 6.92% Short % of Float 9.79% Short Ratio (days to cover) 5.36
Valuation Ratios The PE ratio is -4.03 and the forward
PE ratio is -6.04.
Compass Therapeutics's PEG ratio is
-0.44.
PE Ratio -4.03 Forward PE -6.04 PS Ratio 233.89 Forward PS 68.4 PB Ratio 1.59 P/FCF Ratio -4.43 PEG Ratio -0.44
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Compass Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 14.96,
with a Debt / Equity ratio of 0.05.
Current Ratio 14.96 Quick Ratio 14.96 Debt / Equity 0.05 Debt / EBITDA -0.12 Debt / FCF -0.15 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $24.29K Profits Per Employee $-1.41M Employee Count 35 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 120.25% in the
last 52 weeks. The beta is 1.31, so Compass Therapeutics's
price volatility has been higher than the market average.
Beta 1.31 52-Week Price Change 120.25% 50-Day Moving Average 3.03 200-Day Moving Average 2.4 Relative Strength Index (RSI) 64.13 Average Volume (20 Days) 1,001,791
Income Statement In the last 12 months, Compass Therapeutics had revenue of 850K
and earned -49.38M
in profits. Earnings per share was -0.36.
Revenue 850K Gross Profit 850K Operating Income -56.63M Net Income -49.38M EBITDA -54.87M EBIT -56.63M Earnings Per Share (EPS) -0.36
Full Income Statement Balance Sheet The company has 43.48M in cash and 6.63M in
debt, giving a net cash position of 36.85M.
Cash & Cash Equivalents 43.48M Total Debt 6.63M Net Cash 36.85M Retained Earnings -364.68M Total Assets 116.7M Working Capital 92.34M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -44.85M
and capital expenditures -44K, giving a free cash flow of -44.9M.
Operating Cash Flow -44.85M Capital Expenditures -44K Free Cash Flow -44.9M FCF Per Share -0.33
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -6661.76% and -5808.82%.
Gross Margin 100% Operating Margin -6661.76% Pretax Margin -5808.82% Profit Margin -5808.82% EBITDA Margin -6455.53% EBIT Margin -6661.76% FCF Margin -5282.24%
